Trimi Review: The Cheapest Price in the Category Has a Catch
Trimi advertises the lowest compounded GLP-1 pricing we have found. The price is real. What it costs you is a twelve-month commitment to a category the FDA is actively working to restrict - and that trade needs stating plainly.
Last updated: August 3, 2026
Quick Verdict
Trimi Health has the most aggressive pricing in compounded GLP-1 telehealth, and the pricing only works if you commit to a year. On the annual plan, compounded semaglutide is $99/month and compounded tirzepatide is $125/month - roughly $1,500/year all-inclusive for tirzepatide, including medication, a US-licensed clinician, free shipping and unlimited provider messaging.
Without that commitment the picture changes considerably. Tirzepatide runs about $199/month billed quarterly and $235/month billed monthly - so the headline price reflects a 47% discount for prepaying twelve months.
The genuinely good part: pricing is flat across all dose levels. In a category where cost routinely climbs as you titrate, that is a real structural advantage and the thing we would praise Trimi for above its headline number.
Pricing Across All Three Plans
| Billing Plan | Compounded Tirzepatide | Commitment |
|---|---|---|
| Annual | $125/month (~$1,500/year) | 12 months |
| Quarterly | ~$199/month | 3 months |
| Monthly | $235/month | None |
| Semaglutide, annual | $99/month | 12 months |
Included at every tier: medication, a US-licensed clinician, free shipping, and unlimited provider messaging. That is a genuinely all-inclusive structure - no separate membership fee stacked on top, which is more than several better-known competitors manage.
The number to compare against other providers is $235, not $125 - unless you are genuinely prepared to commit twelve months up front. At $235/month with no commitment, Trimi is competitive but not remarkable. The $125 figure buys a year of exposure, and the next section explains why that exposure is not trivial right now.
Flat Dose Pricing: The Underrated Feature
Trimi's pricing is flat across all dose levels, and this deserves more attention than it gets.
Dose-tiered pricing is common and it works against you in a specific way: your cost rises exactly when your dose does, which is exactly when you are most established on therapy and least likely to switch. Brand-name self-pay pricing does this too - Ozempic tablets run $149 at the starting dose and $299 at maintenance, as covered in our Ozempic pill cost guide.
A flat rate means the price you are quoted at signup is the price you pay at 15 mg. That is genuinely consumer-friendly, and it makes budgeting possible in a category where most people cannot forecast their own costs six months out.
The FDA Compounding Problem
This is the most important section of this review, and it applies to every compounded GLP-1 provider - not just Trimi.
Mass compounding of semaglutide and tirzepatide was permitted largely because both drugs were on the FDA's shortage list. That basis has been removed:
- December 19, 2024: the FDA issued a declaratory order confirming the tirzepatide shortage was resolved.
- February 2025: the FDA determined the semaglutide injection shortage was resolved, and set out phased enforcement policies for compounders.
- Since then: the FDA has proposed excluding semaglutide, tirzepatide and liraglutide from the 503B bulks list, finding no clinical need for outsourcing facilities to compound them. Pharmacy Times characterized this as the FDA moving to permanently close the door on compounded GLP-1s.
Why This Matters for a 12-Month Prepay
You would be prepaying a year for a product category the FDA is actively restricting. If access to compounded semaglutide or tirzepatide is curtailed during your term, what happens to your money is a contractual question - and one you should get answered in writing before you pay.
Ask specifically: "If compounded tirzepatide becomes unavailable during my 12-month term, do I receive a refund for the unused portion, a substitute product, or neither?" A clear answer is reassuring. A vague one is your answer.
To be fair to Trimi: this is a category-wide regulatory situation, not a company failing, and compounded medication from a licensed pharmacy is legal medicine, not a black-market product. But the risk profile of a twelve-month commitment is materially different in 2026 than it was two years ago, and a $99 price that assumes twelve months of availability is pricing an assumption you may not want to buy. Our full guide to the FDA status of compounded GLP-1s covers the complete timeline, and our compounded semaglutide guide covers how to evaluate a pharmacy.
What Users Report
Independent feedback on Trimi is thinner than for the larger providers, which is itself a data point. One aggregator lists Trimi Health at 3.8 stars from 62 reviews across 8 plans.
Sixty-two reviews is a small sample. It is not a red flag - every company starts somewhere - but it means you have less collective experience to draw on than with a provider carrying thousands of reviews, and 3.8 is solid rather than outstanding.
Practical implication: the less independent feedback exists, the more weight the commitment question carries. Committing twelve months to a provider with a large public track record is a different risk from committing twelve months to one with sixty-two reviews. Starting monthly and upgrading later costs you the discount but buys you information.
Trimi vs the Alternatives
| Provider | No-Commitment Price | Best Price | Trade-off |
|---|---|---|---|
| Trimi | $235/mo | $125/mo (12-mo prepay) | Annual exposure to compounding risk |
| Fridays | ~$199/mo | ~$117/mo (annual) | Same annual-commitment structure |
| Ozempic tablets (brand) | $149-$299 by dose | $149 starter only | FDA-approved; price climbs with dose |
| All-inclusive telehealth | $199-$399/mo | Varies | Higher headline, no lock-in |
The honest summary: on price alone, Trimi wins. If cost is the binding constraint and you are comfortable with the commitment and the regulatory picture, $125/month flat across all doses is hard to beat. What you are trading away is optionality at exactly the moment optionality has value.
Who It Suits
Good Fit
- Cost is your binding constraint and you have done the math
- You have already tolerated a GLP-1 and know you can stay on it
- You expect to titrate high - flat dose pricing pays off most there
- You have read the refund terms for a mid-term disruption
- You want medication and clinician access in one price
Poor Fit
- This is your first GLP-1 and you do not know how you will tolerate it
- You are uncomfortable prepaying for compounded medication
- You specifically want FDA-approved brand-name product
- You could not absorb the loss if the term were disrupted
- You want a large independent review base behind your choice
The first-timer point matters most. A meaningful share of people stop GLP-1s during titration because of nausea and other GI effects - see our guides to managing nausea and GLP-1 constipation. Prepaying twelve months before you know whether you tolerate the drug is the single most expensive mistake available in this category.
Frequently Asked Questions
How much does Trimi tirzepatide cost?
It depends entirely on billing plan: $125/month on the annual plan (about $1,500/year), roughly $199/month billed quarterly, and $235/month billed monthly. Compounded semaglutide is $99/month on the annual plan. All tiers include medication, a US-licensed clinician, free shipping and unlimited provider messaging, and pricing is flat across all dose levels.
Is Trimi legit?
It appears to be a real telehealth provider using US-licensed clinicians and compounded medication, with an aggregator rating of 3.8 stars from 62 reviews. That is a small review base compared to the major providers - not a red flag, but less collective experience to draw on. The more substantive concern is not the company but the category: compounded GLP-1s face active FDA restriction.
Should I take the annual plan to get $125/month?
Only if you have already tolerated a GLP-1 and can absorb the loss if the term is disrupted. The discount is real - about 47% off the monthly rate - but you are prepaying twelve months for compounded medication while the FDA has proposed excluding semaglutide and tirzepatide from the 503B bulks list. Get the refund terms for a mid-term disruption in writing first.
Is compounded tirzepatide still legal?
Compounded medication from a licensed pharmacy is legal medicine, but the regulatory basis has narrowed sharply. The FDA resolved the tirzepatide shortage in December 2024 and the semaglutide shortage in February 2025, establishing phased enforcement, and has since proposed excluding both from the 503B bulks list on the grounds that there is no clinical need. Treat long commitments accordingly.
Why does flat dose pricing matter?
Because most pricing in this category rises with your dose, meaning your cost increases exactly when you are most established on therapy and least likely to switch. Brand-name self-pay pricing does this too. A flat rate means the price quoted at signup is the price at your maintenance dose, which makes budgeting possible.
Trimi or Fridays - which is cheaper?
Fridays advertises compounded semaglutide from about $117/month on an annual plan against Trimi's $99, but Trimi's $125 tirzepatide undercuts Fridays' $198. Both use the same annual-commitment structure, so compare at the medication you actually want and at the no-commitment rate you would pay if you did not prepay.
What if I have never taken a GLP-1 before?
Start monthly, not annually. A meaningful share of people discontinue during titration because of nausea and other GI effects, and prepaying twelve months before you know how you tolerate the drug is the most expensive mistake available in this category. You can always upgrade to the annual plan once you know it works for you.
Medical Disclaimer
This article is for informational purposes only and does not constitute medical advice. HealthyPound is not affiliated with Trimi Health. Pricing reflects publicly advertised rates at the time of writing and changes frequently - verify current pricing, commitment terms and refund policy directly with the provider before enrolling. Compounded medications are not FDA-approved and are not evaluated by the FDA for safety, effectiveness or quality; the regulatory status of compounded semaglutide and tirzepatide is subject to ongoing FDA action. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. HealthyPound may receive compensation from affiliate partners mentioned in this article. See our affiliate disclosure and full medical disclaimer.